Literature DB >> 12908768

Proteolytic processing of foamy virus Gag and Pol proteins.

R M Flügel1, K I Pfrepper.   

Abstract

The foamy viral proteases (FV PRs) are set apart from other retroviral processing enzymes by unique features. The first remarkable property is that FV PRs are enzymatically active as high-molecular-mass Pro-Pol proteins. Hence there exist multiple forms of active FV PRs that likely contribute to cleavage site specificity. A FV PR of low molecular size is not detectable in purified virions, in contrast to PRs of other retroviruses that are found in virus particles. Because the major part of Pol remains attached to the amino-terminal enzymatically active PR protein region, the FV-specific way of expressing Pro-Pol polyproteins from a pol-specific transcript provides for the incorporation of Pro-Pol and IN into virus particles. Proteolytic processing of Gag and Pol proteins is incomplete and delayed. Another novel feature is that the catalytic center of the active dimers of cat FV PR consists of D-S/T-Q instead of D-S/T-G, an unprecedented feature of this enzyme. The temporal and spatial control and the factors that regulate FV PRs remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12908768     DOI: 10.1007/978-3-642-55701-9_3

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  30 in total

1.  Role of the C terminus of foamy virus Gag in RNA packaging and Pol expression.

Authors:  Carolyn R Stenbak; Maxine L Linial
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  RNA and protein requirements for incorporation of the Pol protein into foamy virus particles.

Authors:  Katrin Peters; Tatiana Wiktorowicz; Martin Heinkelein; Axel Rethwilm
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Protease-dependent uncoating of a complex retrovirus.

Authors:  Jacqueline Lehmann-Che; Marie-Lou Giron; Olivier Delelis; Martin Löchelt; Patricia Bittoun; Joelle Tobaly-Tapiero; Hugues de Thé; Ali Saïb
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Correct capsid assembly mediated by a conserved YXXLGL motif in prototype foamy virus Gag is essential for infectivity and reverse transcription of the viral genome.

Authors:  Ingrid Mannigel; Annett Stange; Hanswalter Zentgraf; Dirk Lindemann
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Basic residues in the foamy virus Gag protein.

Authors:  Daniel Matthes; Tatiana Wiktorowicz; Juliane Zahn; Jochen Bodem; Nicole Stanke; Dirk Lindemann; Axel Rethwilm
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

6.  Prototype foamy virus protease activity is essential for intraparticle reverse transcription initiation but not absolutely required for uncoating upon host cell entry.

Authors:  Sylvia Hütter; Erik Müllers; Nicole Stanke; Juliane Reh; Dirk Lindemann
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

7.  Distinct Particle Morphologies Revealed through Comparative Parallel Analyses of Retrovirus-Like Particles.

Authors:  Jessica L Martin; Sheng Cao; Jose O Maldonado; Wei Zhang; Louis M Mansky
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

8.  Early reverse transcription is essential for productive foamy virus infection.

Authors:  Alessia Zamborlini; Noémie Renault; Ali Saïb; Olivier Delelis
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

9.  Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.

Authors:  Helga Eizert; Pálma Bander; Péter Bagossi; Tamás Sperka; Gabriella Miklóssy; Péter Boross; Irene T Weber; József Tözsér
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

10.  Restriction of foamy viruses by primate Trim5alpha.

Authors:  Melvyn W Yap; Dirk Lindemann; Nicole Stanke; Juliane Reh; Dana Westphal; Helmut Hanenberg; Sadayuki Ohkura; Jonathan P Stoye
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.